GovChime
Notice ID: 1b4dc95103b348fe8d1f0aed614fc920Solicitation

Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program

Responses closed . Full description on SAM.gov.

Overview

Response deadline
12:00 PM CDT
Posted
October 8, 2026
Notice type
Solicitation
Set-aside
No Set aside used
NAICS
325412: Pharmaceutical Preparation Manufacturing
Agency
Department of WarDEFENSE HEALTH AGENCY (DHA)

Notice details

Office
DEFENSE HEALTH AGENCY (DHA)
Place of performance
San Antonio, Texas, 78230
Last updated
Oct 28, 2026
First published
Last updated on SAM.gov

Identifiers

Solicitation number
HT9402-26-Q-9404
Notice ID
1b4dc95103b348fe8d1f0aed614fc920

Description

The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.

P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed:

a.  Adquey - Atopic - Subclass: Topical Agents
b.  Armlupeg - White Blood Cell Stimulants - Subclass: Pegfilgrastims
c.  Beqalzi - Oncological Agents - Non-BTKI for Chronic Lymphocytic Leukemia-Small Lymphocytic Lymphoma
d.  Bixlenvo - Antiretrovirals - Subclass: Combinations
e.  Clotic - Antifungals - Subclass: NA
f.  Etcamah - Breast Cancer Agents - Estrogen Receptor Antagonist
g.  Langlara - Insulins - Subclass: Basal
h.  Lisraya - Targeted Immunomodulatory Biologics – NA
i.  Mimrylo - Hematological Agents – NA
j.  Nuzolvence - Antibiotics – NA
k.  Rasonque - Oncological Agents - Subclass: RAS Inhibitors
l.  Rezenopy - Alcohol Deterrants - Narcotic Antagonists

The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9404.

Pre-quotation teleconference is on October 14, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Contracting Officer

Primary Contact

Secondary Contact

Documents

Files (16)

  • A-3 RFQ HT9402-26-Q-9404 NAD.pdf

    983 KBAdded in Solicitation version 1Posted
    Download
  • A-3 Price List_Adquey-Atopic-Topical Agents.xlsx

    57 KBAdded in Solicitation version 1Posted
    Download
  • A-3 Price List_Armlupeg-White Blood Cell Stim-Pegfilgrastims.xlsx

    49 KBAdded in Solicitation version 1Posted
    Download
  • A-3 Price List - Beqalzi - Onc Agents - Non-BTKI CLL-SLP.xlsx

    45 KBAdded in Solicitation version 1Posted
    Download
  • A-3 Price List_Bixlenvo-Antiretrovirals-Combinations.xlsx

    45 KBAdded in Solicitation version 1Posted
    Download
  • A-3 Price List_Clotic-Antifungals-NA.xlsx

    45 KBAdded in Solicitation version 1Posted
    Download
  • A-3 Price List_Etcamah-Breast Canc Agt-Estrogen Recptr Antag.xlsx

    45 KBAdded in Solicitation version 1Posted
    Download
  • A-3 Price List_Langlara-Insulins-Basal.xlsx

    45 KBAdded in Solicitation version 1Posted
    Download
  • A-3 Price List_Lisraya - TIBs - NA.xlsx

    45 KBAdded in Solicitation version 1Posted
    Download
  • A-3 Price List - Mimrylo - Hematological Agents - NA.xlsx

    45 KBAdded in Solicitation version 1Posted
    Download
  • A-3 Price List - Nuzolvence -Antibiotics - NA.xlsx

    45 KBAdded in Solicitation version 1Posted
    Download
  • A-3 Price List_Rasonque-Oncological Agents-RAS Inhibitors.xlsx

    45 KBAdded in Solicitation version 1Posted
    Download
  • A-3 Price List - Rezenopy - Alcohol Deterrents-Narcotic Antag.xlsx

    45 KBAdded in Solicitation version 1Posted
    Download
  • FAR 52-225-6-Certificate.pdf

    645 KBAdded in Solicitation version 1Posted
    Download
  • Price Appendix FAQ NAD.pdf

    231 KBAdded in Solicitation version 1Posted
    Download
  • DoD Formulary Placement of FDA Newly Approved Drugs.pdf

    83 KBAdded in Solicitation version 1Posted
    Download

Lifecycle

  1. 1
    Version 1SolicitationCurrent

    Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program

    Notice 1b4dc95103b348fe8d1f0aed614fc920 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following May 2026 newly approved drugs will be reviewed: a. Lifyorli - Oncological Agents - Glucocorticoid Receptor Antagonist b. Quiofic - VITAMINS - WATER SOLUBLE c. Widaplik - ANTIHYPERTENSIVE AGENTS – N/A d. Saphnelo – IMMUNOSUPPRESSIVES – N/A The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9302. Pre-quotation teleconference is on May 13, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.
100%
Solicitation05/28/2026
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following February 2027 newly approved drugs will be reviewed: Atebrioz – Skeletal Muscle Relaxants and Combinations – Subclass: NA Emcitate – Thyroid and Antithyroid Agents – Subclass: NA Hibsago – Hepatitis B Agents – Subclass: NA Juvmo – Parkinsons Agents – Subclass: NA Zegfrovy – Lung Cancer – Subclass: EGFR+ NSCLC The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-27-Q-9102. Pre-quotation teleconference is on November 17, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.
98%
Solicitation11/30/2026
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following February 2027 drug classes/subclasses will be reviewed: a. Ophthalmic - Dry Eye Cequa Eysuvis Miebo Tryptyr Tyrvaya Verkazia Vevye Xiidra b. Testosterone Replacement Therapy - Orals Jatenzo Kyzatrex Tlando The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-27-Q-9101. Pre-quotation teleconference is on November 17, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference.
98%
Solicitation12/07/2026
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Awiqli Flextouch - Insulin - Basal b. Cavhanza - Leukemia and Lymphoma Agents - BCR-ABL Tyrosine Kinase Inhibitors c. Lipfendra - Antilipidemics-1 - PCSK-9 d. Trutakna - Nephrology Agents Miscellaneous - NA The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9402. Pre-quotation teleconference is on August 12, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.
98%
Solicitation08/27/2026
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 drug classes/subclasses will be reviewed: a. Atopy - Topical Agents Anzupgo Eucrisa Opzelura Vtama Zoryve b. Lung Cancer - METEX14 Tabrecta Tepmetko The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9401. Pre-quotation teleconference is on August 12, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference.
98%
Solicitation10/01/2026

Additional Details

Solicitation Number

HT9402-26-Q-9404

Archive Date

Apr 26, 2027

Office Address

JBSA FT SAM HOUSTON, TX, 78234